EOLS 10.89 (+0.18%)
US30052C1071Drug ManufacturersDrug Manufacturers - Specialty & Generic

Evolus (EOLS) Financial Metrics

This table shows a selected set of financial data points of Evolus (EOLS). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 -1.08 0 -9.72 599.35M -0.34 202.09M -35.64M -41.81M -61.69M 62.84M
2022 -1.33 0 -5.66 421.05M -0.34 148.62M -87.85M -60.72M -74.41M 53.92M
2021 -0.94 0 -6.92 324.02M -0.2 99.67M -34.36M -63.59M -46.81M 146.26M
2020 -4.83 0 -0.7 113.36M -0.73 56.54M -61.01M -58.38M -163.01M 102.56M
2019 -3.19 0 -3.82 343.65M -0.44 34.93M -97.95M -92.98M -90.03M 109.89M
2018 -1.92 0 -6.2 290.38M -0.29 0 -25.68M -45.93M -46.87M 93.16M
2017 -0.19 0 0 0 -0.04 0 -13.04M -11.51M -4.48M 0
2016 -1.08 0 0 0 -0.25 0 -13.27M -19.65M -20.07M 187K
2015 -1.67 0 0 0 0 0 -36.38M -30.6M -31.11M 4M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.